- Home
- CCEL vs JSPR Comparison
CCEL vs JSPR Comparison
Compare CCEL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEL | JSPR |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Managed Health Care | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 23.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCEL | JSPR |
|---|---|---|
| Price | $3.75 | $0.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 7.8K | ★ 272.2K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $25,384,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $368.00 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $0.62 |
| 52 Week High | $5.52 | $7.19 |
Technical Indicators
Market Signals| Indicator | CCEL | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 40.19 |
| Support Level | $3.18 | $0.81 |
| Resistance Level | $4.08 | $1.03 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 30.43 | 12.81 |
Price Performance
Historical ComparisonAbout CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.